Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients

Rohan Ameratunga¹,²,³*, See-Tarn Woon²,³, Richard Steele²,⁴, Klaus Lehnert⁵,⁶, Euphemia Leung⁶,⁷, Emily S. J. Edwards⁸ and Anna E. S. Brooks⁵,⁶

¹ Department of Clinical Immunology, Auckland Hospital, Auckland, New Zealand, ² Department of Virology and Immunology, Auckland Hospital, Auckland, New Zealand, ³ Department of Molecular Medicine and Pathology, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, ⁴ Department of Respiratory Medicine, Wellington Hospital, Wellington, New Zealand, ⁵ School of Biological Sciences, University of Auckland, Auckland, New Zealand, ⁶ Maurice Wilkins Centre, School of Biological Sciences, University of Auckland, Auckland, New Zealand, ⁷ Auckland Cancer Society Research Centre, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, ⁸ Allergy and Clinical Immunology Laboratory, Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia

*Correspondence: Rohan Ameratunga E rohana@adhb.govt.nz

Keywords: COVID-19, SARS-CoV-2, CVID - common variable immunodeficiency disorders, vaccine responses, antibody deficiency

INTRODUCTION

COVID-19 has had a disastrous impact on the world with over 5 million deaths, hundreds of millions infected and many more plunged into poverty. COVID-19 has affected almost all countries. The origin of the virus is the subject of ongoing study (1–3).

SARS-CoV-2 initially infects the nasal mucosa. The Spike (S) glycoprotein engages cell-surface ACE2. Host proteases including TMPRSS-2 cleave the S glycoprotein, allowing the S2 subunit to fuse with the cell membrane (4). The viral genome is then able to hijack cellular organelles leading to production of daughter virus particles.

In the initial asymptomatic nasal phase, the innate immune system is silenced resulting in an exponential increase in viral progeny. SARS-CoV-2 deploys several mechanisms to evade cytoplasmic viral sensors. Following the nasal phase, the virus infects the lungs, probably by microaspiration from the nasopharynx and stomach (5, 6). Patients suffering pneumonitis experience increasing dyspnoea and have elevated inflammatory markers.

The smaller percentage entering the systemic phase suffer acute respiratory distress syndrome (ARDS) and multiple organ dysfunction. Increased d-dimers indicate a risk of arterial and venous thromboembolic disease. In spite of invasive ventilation and extracorporeal membrane oxygenation, mortality remains very high in such patients.
PATIENTS AT INCREASED RISK

There is a high case fatality rate in the elderly (7). In addition, patients with comorbidities including obesity, diabetes, hypertension, coronary artery disease, malignancy, renal and pulmonary disease are at increased risk of adverse outcomes (7–9). Patients of Black, Hispanic and South Asian origin also have a higher case fatality rate. Inequitable access to healthcare is at least partly responsible for these ethnic differences (10, 11).

Current data also suggests individuals with some immunodeficiency disorders are at increased risk of severe outcomes (12, 13). Patients with innate immune defects and T cell disorders are at greater risk than healthy individuals (14–16). In contrast, most studies indicate patients with X-linked agammaglobulinemia (XLA) without comorbidities appear to be at lower risk, inferring antibodies can in some circumstances be detrimental (17–20). Some authors are however less certain about the protective effect of XLA in COVID-19 outcomes (21, 22).

Immunocompromised patients are at risk of Chronic COVID-19, a dangerous stalemate between SARS-CoV-2 and impaired cellular immunity (23). Patients with Chronic COVID-19 can shed virus for months before either succumbing to or recovering from the infection. Such patients are vulnerable to intra-host viral evolution which could result in variants of high consequence (24). This is a public health emergency and prevention of Chronic COVID-19 is of the utmost priority.

RESPONSE TO COVID-19 VACCINES

Vaccines have proved effective in mitigating COVID-19. Vaccines do not prevent breakthrough infections, but markedly reduce the risk of a destructive immune response (Figure 1) (25). Hospitalisations and deaths from COVID-19 have dramatically decreased following vaccination. Most vaccinated patients dying from breakthrough infections are elderly or those with comorbidities. Vaccinated patients have variable levels of antibodies to the S glycoprotein at the time of breakthrough infections (26). There is no specific antibody level, which reliably prevents breakthrough infection (27, 28). The S glycoprotein is post-translationally modified with carbohydrates and antibody responses are less durable. In many studies antibody levels decrease six months after vaccination (29).

FIGURE 1 | Showing the relationship between T cell defects, responses to vaccines and outcomes. Vaccines shift the disease severity to the milder end of the spectrum. Instead of fatal disease, vaccinated patients with T cell defects will have a milder version of the infection. There is a risk of Chronic COVID-19 in immunodeficient patients and a vigorous T cell response to vaccines shifts the disease severity to the milder end of the spectrum. COVID-19 disease severity according to WHO criteria.
In contrast, memory T cell responses to vaccines correlate with protection (25, 30). Diagnostic T cell assays can be measured on different platforms, depending on the expertise of the laboratory (31). Current COVID-19 vaccines are regarded as T cell dependent and cellular responses are more durable, indicating that waning antibody levels underestimate the duration of protection (32). The S glycoprotein has strong adjuvant properties for cellular immunity, increasing its immunogenicity (and reactogenicity). Current COVID-19 vaccines do not require an additional adjuvant.

## COMMON VARIABLE IMMUNODEFICIENCY DISORDERS AS A MODEL OF IMMUNOCOMPROMISED INDIVIDUALS

Common Variable Immunodeficiency Disorders (CVID) are the most frequent symptomatic primary immune defect in adults and children (33, 34). By definition, the cause of CVID is not known (35–37). In some patients an underlying genetic defect is causative (38). If a causative defect is identified, these patients are considered to have a CVID-like disorder and are removed from the broad umbrella diagnosis of CVID. In non-consanguineous populations approximately 25% have an underlying genetic defect, mostly autosomal dominant disorders (39, 40). In consanguineous societies a much higher number have autosomal recessive disorders (41).

Currently there are three sets of diagnostic criteria for CVID in common use (35–37). The original European Society of Immunodeficiencies/Pan-American Group for Immunodeficiency (ESID/PAGID) 1999 Criteria required significant hypogammaglobulinemia (IgG 2 sd. below the mean) with either impaired vaccine responses or absent isohemagglutinins (42). These were deemed difficult to use (43). In 2013 new diagnostic criteria were proposed with a lower IgG threshold (5 g/L) and vaccine responses beyond protection, to those of normal persons (35). These criteria also contained many of the more recent discoveries including reduction in switched memory B cells and genes predisposing to CVID. In contrast to the previous criteria, impaired vaccine responses were not mandatory for the diagnosis. The revised ESID registry criteria were published in 2014 (36). These were very similar to the Ameratunga et al., criteria (35), but maintained the higher IgG threshold (2 sd. below the mean) and protective vaccine responses of the original ESID/PAGID 1999 Criteria. In 2016 the International Consensus (ICON) document was published (37). Like the original ESID/PAGID 1999 criteria, poor responses to vaccine were mandatory in the ICON 2016 Criteria.

CVID and CVID-like disorders have a spectrum of B and T cell defects. The ESID 2014 and ICON 2016 criteria exclude patients with severe T cell defects, who were deemed to have late onset combined immunodeficiency (LOCID) based on reduced naïve CD4+ T cell proportions (<10% CD4+ T cells) (36, 37). It has however been suggested patients with LOCID should remain within the broad spectrum of CVID and CVID-like disorders (44). Individuals within the same family, carrying the identical NFKB1 mutation, had widely differing immune defects. One brother was in excellent health, while his sister suffered multiple autoimmune complications and malignancy. She met the criteria for LOCID because of reduced T cell subsets and died prematurely from hepatic failure (45, 46).

### CVID AS A MODEL OF VACCINE CHALLENGE RESPONSES IN IMMUNOCOMPROMISED PERSONS

Although not mandatory in the Ameratunga et al., 2013 or ESID 2014 Criteria, vaccine challenge responses are an integral part of the diagnostic work-up of patients with suspected CVID. CVID and other antibody deficiency disorders can serve as a useful model for both susceptibility to COVID-19 as well as responses to vaccines. In contrast to CVID, vaccine challenge responses are not routinely undertaken in patients suffering from secondary immunodeficiency disorders for either diagnosis or prerequisites for therapy. These patients receive subcutaneous or intravenous immunoglobulin (SCIG/IVIG) replacement based on either profound hypogammaglobulinemia or if they have modest hypogammaglobulinemia with breakthrough infections.

Two recent studies have explored the responses to vaccines in patients with hypogammaglobulinemia as well as CVID. In the New Zealand hypogammaglobulinemia study (NZHS), asymptomatic patients with hypogammaglobulinemia (aH GUS) were noted to have an excellent prognosis (45). In this long-term prospective study, only one patient experienced progressive hypogammaglobulinemia requiring SCIG/IVIG. The majority have remained well for over a decade. In contrast, those with symptoms (sHGUS) had a mixed prognosis. Many experienced progressive deterioration culminating in SCIG/IVIG treatment. Vaccine challenge responses in the two groups were indistinguishable. Importantly, both groups had excellent responses to Hib and tetanus toxoid, both T cell dependent antigens. In contrast, responses to diphtheria toxoid and Pneumovax were muted. Poor responses to diphtheria toxoid are common, particularly in the elderly. Pneumovax responses are T cell independent.

A similar outcome was noted in the New Zealand CVID Study (NZCS) (48, 49). Most patients meeting criteria for CVID had excellent responses to tetanus toxoid and Hib. As in the NZHS, the responses to diphtheria toxoid and Pneumovax were suboptimal. This indicated T cell responses were preserved for at least some antigens in CVID. Recent studies confirm many CVID patients may generate protective responses to COVID-19 vaccines (50, 51).

### APPROACH TO IMMUNOCOMPROMISED PATIENTS

The most important outcome of COVID-19 vaccination is a balanced, co-ordinated cellular immune response to the virus (25, 30). This implies at least some T cell function is required for vaccine efficacy (50). Given what was noted in the NZHS and
NZCS, COVID-19 vaccines will provide at least partial protection in most immunocompromised patients. This is a strong argument for vaccinating these patients and monitoring their T cell responses to SARS-CoV-2 (50–52).

Immunocompromised patients should be individually assessed to determine the degree of cellular immune deficiency. The extent of cellular impairment can be ascertained by the types of infections as well as laboratory tests including T cell subsets and their in vitro function. The nature of the underlying disorder and therapy may also help identify impaired cellular immunity. Such an individualised approach can sometimes lead to unexpected findings. Patients treated with rituximab are more susceptible to COVID-19 than those with XLA (53–55). This may be because of the underlying disorder or because of the use of additional immunosuppressive agents.

The WHO, UK and other countries are now advocating a three dose primary COVID-19 immunisation program for immunocompromised persons. This may improve memory T cell responses to the vaccine (56, 57). It remains to be determined if heterologous primary immunisation, with mRNA and adenovirus-based vaccines generates a robust cellular response, as seen with humoral responses in healthy individuals (58). Again, monitoring T cell responses following vaccination will provide reassurance (50, 55).

It will be difficult to monitor antibody responses to COVID-19 vaccines if patients are on SCIG/IVIG. Most plasma donors have high titres of SARS-CoV-2 antibodies from either infection or vaccination (59). SARS-CoV-2 memory B cells could be quantified as a measure of humoral immunity in patients on IVIG/SCIG. These responses have been quantitated in PID patients receiving the influenza vaccine (60).

Antibody responses to the S glycoprotein are T cell dependent. In patients who are not on SCIG/IVIG, a good antibody response could be interpreted as a satisfactory cellular response to the vaccine. In those who have poor antibody responses, it is still possible they have protective T cell responses (50, 55). Many healthy persons failed to seroconvert but had robust T cell responses to SARS-CoV-2 (61). There have been calls for development of diagnostic T cell assays for SARS-CoV-2, which would be very useful for diagnosis or evaluating vaccine responses in immunocompromised patients (31, 61).

The best current advice is for immunocompromised patients including those with antibody deficiency to have at least three primary vaccinations and have their T cell responses measured (56, 57). If there is failure to generate cellular immunity to SARS-CoV-2, these patients should be advised to shelter in place until more effective therapeutics and vaccines are developed for COVID-19. The recent development of antiviral drugs by Merck (molnupiravir) and Pfizer (paxlovid) is encouraging.

Until these drugs are widely available, patients with suboptimal memory T cell responses remain at risk of severe outcomes or Chronic COVID-19 (Figure 1). If there is waning cellular immunity they should receive boosters. In the absence of a diagnostic T cell assay for SARS-CoV-2, booster COVID-19 vaccines could be routinely considered every 6 months or sooner.

**AUTHOR CONTRIBUTIONS**

RA wrote the first draft. All other authors contributed to editing the manuscript.

**ACKNOWLEDGMENTS**

A SARS-CoV-2 T cell assay has not been implemented in NZ.

**REFERENCES**

1. Tiwari R, Dhama K, Sharun K, Iqbal Yatoo M, Malik VS, Singh R, et al. COVID-19: Animals, Veterinary and Zoonotic Links. Vet Q (2020) 40(1):169–82. doi: 10.1080/16521576.2020.1766725
2. Segreto RA, Deign Y. The Genetic Structure of SARS-CoV-2 Does Not Rule Out a Laboratory Origin: SARS-COV-2 Chimeric Structure and Furin Cleavage Site Might be the Result of Genetic Manipulation. Bioessays (2021) 43(3):e2000240. doi: 10.1002/bies.202000240
3. Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, et al. The Origins of SARS-CoV-2: A Critical Review. Cell (2021) 184(19):4848–56. doi: 10.1016/j.cell.2021.08.017
4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020) 4(20):30229–4. doi: 10.1016/j.jci.2020.02.052
5. Baek WK, Sohn SY, Mahgoub A, Hage R. A Comprehensive Review of Severe Acute Respiratory Syndrome Coronavirus 2. Cureus (2020) 12(5):e7943. doi: 10.7759/cureus.7943
6. Ameratunga R, Woon ST, Steele R, Snell R, Medlicott N, Mears E, et al. Perspective: The Nose and the Stomach Play a Critical Role in the NZaCE2-Patari” (Modified ACE2) Drug Treatment Project of SARS-CoV-2 Infection. Expert Rev Clin Immunol (2021) 17(6):553–60. doi: 10.1080/1744666X.2021.1912596
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet (Lond Engl) (2020) 395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3
8. Weiss P, Murdoch DR. Clinical Course and Mortality Risk of Severe COVID-19. Lancet (Lond Engl) (2020) 395(10229):1014–5. doi: 10.1016/S0140-6736(20)30631-4
9. Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of Immunosuppression and Immunodeficiency on COVID-19: A Systematic Review and Meta-Analysis. J Infect (2020) 81(2):e93–5. doi: 10.1016/j.jinf.2020.05.017
10. Abedi V, Olulana O, Avula V, Chaudhary D, Khan A, Shahjouei S, et al. Racial, Economic, and Health Inequality and COVID-19 Infection in the United States. J Racial Ethic Health Disparities (2021) 8(3):732–42. doi: 10.1080/1744666X.2020.1822380
11. Pham HK, Tran TQ, Pham CL, Tran TT, Le TT, Tran TH, et al. Coronavirus Disease 2019 in Patients With Primary Immunodeficiency: The United Kingdom Experience. J Allergy Clin Immunol (2021) 147(3):870–8. doi: 10.1016/j.jaci.2020.09.010
12. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus Disease 2019 in Patients With Inborn Errors of Immunity: An International Study. J Allergy Clin Immunol (2021) 147(2):520–31. doi: 10.1016/j.jaci.2020.09.010
13. Shields AM, Burns SO, Savic S, Richter AG. Coronavirus Disease 2019 in Patients With Primary and Secondary Immunodeficiency: The United Kingdom Experience. J Allergy Clin Immunol (2021) 147(3):870–5. doi: 10.1016/j.jaci.2020.12.620
14. Esenboga S, Ocak M, Akarsu A, Bildik HN, Cagdas D, Iskit AT, et al. COVID-19 in Patients With Primary Immunodeficiency. J Clin Immunol (2021) 41(7):1355–22. doi: 10.1007/s10875-021-01065-9
15. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Auto-Antibodies Against Type I IFNs in Patients With Life-Threatening COVID-19. *Science* (2020) 370(650):1305–6. doi: 10.1126/science.abc6598.

16. Zhang QA, Bastard PA, Liu Z, Le Pen JA, Moncada-Velez MA, Chen J, et al. Inborn Errors of Type I IFN Immunity in Patients With Life-Threatening COVID-19. *Science* (2020) 370(6515):eabd4585. doi: 10.1126/science.abc4585.

17. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A Possible Role for B Cells in COVID-19? Lessons From Patients With Agammaglobulinemia. *J Allergy Clin Immunol* (2020) 146(1):253–4. doi: 10.1016/j.jaci.2020.04.013.

18. Jin H, Reed JC, Liu STH, Ho HE, Lopes JP, Ramsey NB, et al. Three Patients With X-Linked Agammaglobulinemia Hospitalized for COVID-19 Improved With Convalescent Plasma. *J Allergy Clin Immunol Infect Pract* (2020) 8(10):3594–6.e3. doi: 10.1016/j.jaip.2020.08.059.

19. Mira E, Yarce OA, Ortega C, Fernandez S, Pascual NM, Gomez C, et al. Rapid Recovery of a SARS-CoV-2-Infected X-Linked Agammaglobulinemia Patient After Infusion of COVID-19 Convalescent Plasma. *J Allergy Clin Immunol Infect Pract* (2020) 8(8):2793–5. doi: 10.1016/j.jaip.2020.06.046.

20. Van Damme KFA, Tavernier S, Van Roy N, De Leeuw E, Declercq J, Bosteels H, et al. Case Report: Convalescent Plasma, a Targeted Therapy for Patients With COVID and Severe COVID-19. *Front Immunol* (2021) 11(1664-3224):979671. doi: 10.3389/fimmu.2020.979671.

21. Donoford MJ, Shillowe BM, Humphreys IR, Gennery AR, Jolles S. COVID-19 and X-Linked Agammaglobulinemia (XLA) - Insights From a Monogenic Antibody Deficiency. *Curr Opin Allergy Clin Immunol* (2021) 21(6):525–34. doi: 10.1097/ACI.0000000000000792.

22. Grammatikos A, Donati M, Johnston SL, Gompels MM. Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies. *Front Immunol* (2021) 12(1664-3224):731643. doi: 10.3389/fimmu.2021.731643.

23. Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, et al. CVID Is a Model for COVID Vaccines. *CVID Is a Model for COVID Vaccines.* Front Immunol (2021) 12:6724:596761. doi: 10.3389/fimmu.2020.00748.

24. Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham-Rundles C, et al. Auto-Antibodies Against Type I IFNs in Patients With Life-Threatening COVID-19. *Autoimmun Rev* (2021) 21. doi: 10.1016/j.autrev.2021.10.007.

25. Bertoletti A, Le Bert N, Qui M, Tan AT. SARS-CoV-2-Specific T Cells in Patients With Common Variable Immunodeficiency Disorders. *Cell* (2021) 189(20):4073–40. doi: 10.1016/j.cell.2021.09.010.

26. Lorenzini T, Fliegauf M, Klammer N, Frede N, Proietti M, Bulashevska A, et al. Beyond T Cell Assays in the Diagnosis of Common Variable Immunodeficiency Disorders. *Clin Rev Allergy Immunol* (2021) 6:238. doi: 10.1007/s12016-020-08860-7.

27. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. *J Allergy Clin Immunol Infect Pract* (2019) 7(6):1763–70. doi: 10.1016/j.jaip.2019.02.004.

28. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. COVID-19 Breakthrough Infections in Vaccinated Health Care Residents. *Vaccines (Basel)* (2020) 8(9):859. doi: 10.3390/vaccines8080859.

29. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipshitz M, Cohen C, et al. COVID-19 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med* (2021) 385(16):1474–84. doi: 10.1056/NEJMoa2109072.

30. Pegu AA, O’Connell S, Schmidt SA, O’Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 Vaccine-Induced Antibodies Against SARS-CoV-2 Variants. *Science* (2021) 373(6561):1372–7. doi: 10.1126/science.abj1476.

31. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. A BNT162b2 Vaccine Induces Neutralizing Antibodies and Poly-Specific T Cells in Humans. *Nature* (2021) 595(7868):572–7. doi: 10.1038/s41586-021-03636-3.

32. Ameratunga R, Ahn Y, Jordan J, Lehnert K, Swoon ST. Keeping It in the Family: The Case for Considering Late-Onset Combined Immunodeficiency as a Subset of Common Variable Immunodeficiency Disorders. *Expert Rev Clin Immunol* (2018) 14(7):549–56. doi: 10.1080/1744666X.2018.1481750.

33. Flega M, Bryant VL, Frede N, Slade C, Swoon ST, Lehnert K, et al. Haploinsufficiency of the NF-Kappa Beta 1 Subunit P50 in Common Variable Immunodeficiency. *Am J Hum Genet* (2015) 97(3):389–403. doi: 10.1016/j.ajhg.2015.07.008.

34. Ameratunga R, Ahn Y, Jordan J, Lehnert K, Swoon ST. Characterization of the Clinical and Immunological Phenotype and Management of 157 Individuals With 56 Distinct Heterozygous NFκB1 Mutations. *J Allergy Clin Immunol* (2020) 92(10):577–80. doi: 10.1016/j.jaci.2019.11.051.

35. Ameratunga R, Ahn Y, Steele R, Swoon ST. Bronchiectasis Is Associated With Delayed Diagnosis and Adverse Outcomes in the New Zealand Common Variable Immunodeficiency Disorders Cohort Study. *Clin Exp Immunol* (2021) 204(3):352–60. doi: 10.1111/cei.13595.

36. Ameratunga R, Longhurst H, Steele R, Swoon ST. Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorders (CVID) in the New Zealand CVID Cohort Study. *Clin Rev Allergy Immunol* (2021) 61(2):236–44. doi: 10.1007/s12016-021-08860-7.

37. Amadio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and Cellular Response Following Vaccination. *Expert Rev Clin Immunol* (2021) 18(10):2307–32. doi: 10.1097/ACI.0000000000002047.
mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Front Immunol (2021) 12(1664–3224). doi: 10.3389/fimmu.2021.727850

51. Salinas AF, Mortari EP, Terreiri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does Their Best. J Clin Immunol (2021) 41(8):1709–22. doi: 10.1007/s10875-021-01133-0

52. Ameratunga R, Longhurst H, Steele R, Lehert K, Leung E, Brooks AES, et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does Their Best. J Clin Immunol (2021) 41(8):1709–22. doi: 10.1007/s10875-021-01133-0

53. Ameratunga R, Longhurst H, Steele R, Lehert K, Leung E, Brooks AES, et al. Common Variable Immunodeficiency Disorders, T Cell Responses to SARS-CoV-2 Vaccines and the Risk of Chronic COVID-19. J Allergy Clin Immunol Pract (2021) 9(10):3575–83. doi: 10.1016/j.jaip.2021.06.019

54. Levavi HA-O, Lancman GA, Gabrilove JA. Impact of Rituximab on COVID-19 Outcomes. Ann Hematol (2021) 100(11):2805–12. doi: 10.1007/s00277-021-04662-1

55. Marasco V, Carniti CA, Guidetti A, Farina L, Magni M, Miceli R, et al. T-Cell Immune Response After mRNA SARS-CoV-2 Vaccines Is Frequently Detected Also in the Absence of Seroconversion in Patients With Lymphoid Malignancies. Br J Haematol (2021) 110(11):17877. doi: 10.1111/bjh.17877

56. Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med (2021) 385(13):1244–6. doi: 10.1056/NEJMoa2111462

57. Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune Responses to Two and Three Doses of the BNT162b2 mRNA Vaccine in Adults With Solid Tumors. Nat Med (2021) 27(11):2002–11. doi: 10.1038/s41591-021-01542-x

58. Benning LA, Töllner M, Hidmark A, Schaier MA, Nussdag BA, Källbe F, et al. Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses Among Health Care Workers. Vaccines (Basel) (2021) 9(8):857. doi: 10.3390/vaccines9080857

59. Dodd RA, Notari EP, Brodsky JP, Foster GA, Xu M, Saá P, et al. Patterns of Antibody Response to SARS-CoV-2 Among 1.6 Million Blood Donors: Impact of Vaccination, United States December 2020 - June 2021. J Infect Dis (2021) 215(3):1199. doi: 10.1093/infdis/jia514

60. Hartley GA, Edwards EA, Bosco JA, Ojaimi SA, Stirling RA, Cameron PA, et al. Influenza-Specific IgG1(+) Memory B-Cell Numbers Increase Upon Booster Vaccination in Healthy Adults But Not in Patients With Predominantly Antibody Deficiency. Clin Transl Immunol (2021) 9(10):e1199. doi: 10.1002/cti2.1199

61. Ameratunga RA, Woon ST, Jordan A, Longhurst H, Leung EA, Steele R, et al. Response to Letter to the Editor: The Clinical Utility of Diagnostic T Cell Assays for COVID-19. Expert Rev Clin Immunol (2021) 17(11):1159–61. doi: 10.1080/1744666X.2021.1982386

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ameratunga, Woon, Steele, Lehert, Leung, Edwards and Brooks. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.